Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Immunology-Based Cancer Treatment: Building on the Promise of the Past
- Mobilizing the Human Immune System: Back to the Future
- Observations in Bladder Cancer Patients
- Observations in Melanoma Patients
- Marketed Immunomodulatory Oncology Drugs
- Novartis' s Proleukin
- Roche' s Roferon-A and Schering' s Intron-A
- Thalidomide and Thalidomide Derivatives
- Thalidomide
- Celgene' s Thalidomide Derivatives
- Revlimid (Lenalidomide)
- CC-4047
- CC-11006
- Small-Molecule Drugs that Modulate Toll-Like Receptors
- 3M Pharmaceuticals' Aldara
- 3M Pharmaceuticals' 852A
- Coley Pharmaceuticals/Pfi zer' s PF-3512676
- Dynavax Technologies' 1018 ISS
- Idera Pharmaceuticals' IMOs
- Mologen' s dSLIM
- Biologics That Modulate T-Cell Costimulation
- CTLA-4 Antagonists
- Amgen/Pfi zer' s Tremelimumab
- Medarex/Bristol-Myers Squibb' s Ipilimumab
- CD28 Superagonist TGN1412
- Outlook
Tables:
- 1. Marketed Nonspecifi c Immunomodulatory Drugs for Cancer
- 2. Celgene' s Immunomodulatory Products for Cancer Indications
- 3. Toll-Like Receptor Agonists in Clinical Development for Cancer
Treatment, 2007
- 4. T-Cell Costimulation Modulating Biologics in Development for Cancers
- 5. Potential Reasons for the Pathogenic Effect of TGN1412 in Humans
Figures:
- 1. Chemical Structures of Thalidomide and Lenalidomide
- 2. Mechanisms of T-Cell Costimulation
Sidebar:
- Thalidomide Derivatives vs. Thalidomide: How Is Cancer Immunomodulation
Best Achieved?
|
Related Report
|
View Cart
